Source: Eur Respir Monogr 2020; 88: 251-263
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Dharani Narendra, Nicola A. Hanania. Impact of inhaled corticosteroids in patients with cardiovascular disease. Eur Respir Monogr 2020; 88: 251-263

Member's Comments

No comment yet.

Related content which might interest you: Inhaled corticosteroids and the risk of a first exacerbation in COPD patients Source: Eur Respir J 2004; 23: 692-697 Year: 2004 Effectiveness and safety of concurrent beta-blockers and inhaled bronchodilators in COPD with cardiovascular comorbidities Source: Eur Respir Rev, 26 (145) 160123; 10.1183/16000617.0123-2016 Year: 2017 Risk of myocardial infarction and cardiovascular death associated with inhaled corticosteroids in COPD Source: Eur Respir J 2010; 35: 1003-1021 Year: 2010 Osteoporosis risk assessment in elderly male patients with COPD who use inhaled corticosteroids Source: Annual Congress 2006 - COPD therapy Year: 2006 Inhaled corticosteroids and hospitalisation due to exacerbation of COPD Source: Eur Respir J 2003; 22: 286-289 Year: 2003 Low-dose inhaled and nasal corticosteroid use and the risk of cataracts Source: Eur Respir J 2006; 27: 1168-1174 Year: 2006 Osteoporosis in patients with long-term inhaled corticosteroids treatment Source: Eur Respir J 2007; 30: Suppl. 51, 613s Year: 2007 Modelling the beneficial impact of inhaled corticosteroids on health outcomes among COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 290s Year: 2004 Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results Source: Eur Respir J 2009; 34: 641 Year: 2009 Impact of inhaled corticosteroid use on outcome in COPD patients hospitalised with pneumonia Source: Annual Congress 2010 - Aetiology and outcomes of infective exacerbations of COPD Year: 2010 Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events Source: Eur Respir J, 49 (5) 1602245; 10.1183/13993003.02245-2016 Year: 2017 Inhaled corticosteroids and the risk of pneumonia in Medicare patients with COPD Source: Annual Congress 2012 - COPD: risk factors, biomarkers and diagnosis Year: 2012 Use of inhaled corticosteroids and the risk of depressive symptoms in patients with chronic obstructive pulmonary disease Source: Virtual Congress 2021 – Lung disease burden and management Year: 2021 Osteoporosis risk associated with chronic corticoid inhalation therapy in patients with COPD Source: Annual Congress 2009 - Prognosis and comorbidities in COPD Year: 2009 Are inhaled corticosteroids increasing the “load” for some patients with COPD? Source: Eur Respir J, 50 (4) 1701848; 10.1183/13993003.01848-2017 Year: 2017 Patients‘ reasons for early discontinuation of inhaled corticosteroids and their disease control Source: Eur Respir J 2007; 30: Suppl. 51, 285s Year: 2007 Dose dependent increased mortality risk in COPD patients treated with oral glucocorticoids Source: Eur Respir J 2001; 17: 337-342 Year: 2001 Patients with moderate asthma symptoms may benefit from short-term inhaled corticosteroid monotherapy Source: Eur Respir J 2007; 30: Suppl. 51, 615s Year: 2007 Duration of systemic corticosteroids treatment in COPD exacerbations Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008